Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.180
+0.030 (2.61%)
At close: Feb 27, 2026, 4:00 PM EST
1.160
-0.020 (-1.69%)
After-hours: Feb 27, 2026, 7:23 PM EST
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$698,222
Market Cap
11.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | 18 | 2 | 12.50% | 17 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| BioLineRx | 28 |
| Longeveron | 25 |
| Imunon | 25 |
| Cardio Diagnostics Holdings | 15 |
| Traws Pharma | 7 |
| Phio Pharmaceuticals | 5 |
| Pulmatrix | 2 |
SNGX News
- 2 days ago - Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 4 days ago - Soligenix to Present at BIO Investment & Growth Summit - PRNewsWire
- 16 days ago - Soligenix Details Recent Progress and Upcoming Milestones - PRNewsWire
- 2 months ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 2 months ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 2 months ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 3 months ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 3 months ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire